Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial

被引：11
|
作者：
Sternberg, Cora N.
De Bono, Johann Sebastian
Chi, Kim N.
Fizazi, Karim
Mulders, Peter
Hirmand, Mohammad
Forer, David
Scher, Howard I.
机构：
[1] San Camillo & Forlanini Hosp, Rome, Italy
[2] Inst Canc Res, Sutton, Surrey, England
[3] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada
[4] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[5] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[6] Medivation Inc, San Francisco, CA USA
[7] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer
    Desai, Kunal B.
    Serritella, Anthony V.
    Stadler, Walter M.
    O'Donnell, Peter H.
    Sweis, Randy F.
    Szmulewitz, Russell Z.
    CLINICAL CANCER RESEARCH, 2024, 30 (11) : 2384 - 2392
  • [42] Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial
    Lorente, D.
    De Velasco Oria, G. A.
    Carles, J.
    Gillessen, S.
    Fizazi, K.
    Joshua, A.
    Eisenberger, M.
    Sartor, O.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    Powles, Thomas
    Yuen, Kobe C.
    Gillessen, Silke
    Kadel, Edward E.
    Rathkopf, Dana
    Matsubara, Nobuaki
    Drake, Charles G.
    Fizazi, Karim
    Piulats, Josep M.
    Wysocki, Piotr J.
    Buchschacher, Gary L., Jr.
    Alekseev, Boris
    Mellado, Begona
    Karaszewska, Boguslawa
    Doss, Jennifer F.
    Rasuo, Grozdana
    Datye, Asim
    Mariathasan, Sanjeev
    Williams, Patrick
    Sweeney, Christopher J.
    NATURE MEDICINE, 2022, 28 (01) : 144 - +
  • [44] Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Wang, Hao
    Luber, Brandon
    Nakazawa, Mary
    Chen, Yan
    Roeser, Jeffrey C.
    Fedor, Helen L.
    Lotan, Tamara L.
    Zheng, Qizhi
    De Marzo, Angelo M.
    Isaacs, John T.
    Isaacs, William B.
    Nadal, Rosa
    Paller, Channing Judith
    Denmeade, Samuel R.
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Luo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    Thomas Powles
    Kobe C. Yuen
    Silke Gillessen
    Edward E. Kadel
    Dana Rathkopf
    Nobuaki Matsubara
    Charles G. Drake
    Karim Fizazi
    Josep M. Piulats
    Piotr J. Wysocki
    Gary L. Buchschacher
    Boris Alekseev
    Begoña Mellado
    Bogusława Karaszewska
    Jennifer F. Doss
    Grozdana Rasuo
    Asim Datye
    Sanjeev Mariathasan
    Patrick Williams
    Christopher J. Sweeney
    Nature Medicine, 2022, 28 : 144 - 153
  • [46] Relationship between quality of life (QoL) and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy: Results from the AFFIRM study.
    Miller, Kurt
    Cella, David
    De Phung
    Naidoo, Shevani
    Holmstrom, Stefan
    Ivanescu, Cristina
    Skaltsa, Konstantina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
    Tucker, Matthew D.
    Zhu, Jason
    Berry, William R.
    Ramalingam, Sundhar
    Zhang, Tian
    Harrison, Michael Roger
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [48] A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Aggarwal, Rahul
    Abida, Wassim
    Schweizer, Michael
    Pantuck, Allan
    Nanus, David
    Heath, Elisabeth
    Lakhotia, Sanjay
    Hansen, Henrik
    Silverman, Michael
    Bauman, Lisa
    Snyder, Margo
    Campeau, Eric
    Norek, Karen
    Attwell, Sarah
    O'Farrell, Marie
    Smith, Steve
    Wegge, Philip
    Jahagirdar, Ravi
    Alumkal, Joshi
    CANCER RESEARCH, 2019, 79 (13)
  • [49] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Prognostic Factors in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide (ENZA) Or Bicalutamide (BIC) in Terrain
    Corcoran, N. M.
    Heidenreich, A.
    Shore, N.
    Villers, A.
    Klotz, L.
    Siemens, D. R.
    van Os, S.
    Baron, B.
    Wang, F.
    Chowdhury, S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 57 - 57
12345